Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, ...

Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where Street ...

Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary.

The price target increase follows what Jefferies described as a "robust COPD launch trajectory" for Ohtuvayre, Verona’s PDE3/4 nebulizer treatment. The medication generated $71 million in sales during ...

Jefferies also reiterated a Buy rating with a $95 target, emphasizing that Verona Pharma’s drug Ohtuvayre could potentially achieve between $3-5 billion in peak sales, despite competition from ...

Additionally, Verona Pharma is conducting a Phase 2 trial of ensifentrine, which is 80% powered to detect a hazard ratio of 0.6 and includes a COPD overlap. Piper Sandler analysts expressed optimism ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating.

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.